updated 5/10/2010 1:36:03 PM ET 2010-05-10T17:36:03

Biopharmaceutical company Progenics Pharmaceuticals Inc. said Monday its first-quarter loss widened, as research and development revenue sank compared to last year, when the company also received a $15 million payment.

The Tarrytown, N.Y., company said it lost $18.6 million, or 58 cents per share, in the three months that ended March 31. That compares to a loss of $1.8 million, or 6 cents per share, in the first quarter of 2009.

First-quarter revenue dropped to $1.5 million from $20.9 million.

Analysts expected a loss of 41 cents per share on nearly $6 million in revenue, according to a survey by Thomson Reuters.

The company attributed part of its revenue decline to the end of a collaboration with Wyeth, which was purchased by Pfizer Inc. last year. Progenics also recorded a $15-million payment from Ono Pharmaceutical Co. Ltd. in the first quarter of 2009.

Progenics said worldwide sales of the drug Relistor grew 6 percent to $4.2 million in the first quarter. Relistor is designed to treat constipation caused by use of opioid painkillers, which is a common side effect of treatment with those drugs.

The company's expenses also fell 14 percent in the first quarter to $20.1 million, due mainly to lower compensation expenses from a headcount reduction. Research and development expenses fell 20 percent to $11.9 million.

Shares of Progenics fell 10 cents to $5.43 in afternoon trading Monday.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com